OncoMatch/Clinical Trials/NCT07002216
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Is NCT07002216 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for hodgkin lymphoma.
Treatment: Brentuximab Vedotin · Etoposide · Cyclophosphamide · Doxorubicin · Dacarbazine · Dexamethasone — The purpose of this study is to further assess the efficacy and tolerability of a regimen of Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD) in patients with Stage 2 B-IV Hodgkin Lymphoma (HL) with an exploratory objective to assess the clinical utility of Circulating tumor DNA (ctDNA) as a biomarker for minimal residual disease (MRD) and depth of treatment response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage 2B, III, IV (Lugano)
Excluded: Stage I, IIA
Stage 2 B cHL with one or both of the following risk factors: Large mediastinal mass (≥1/3 of the maximum transverse thoracic diameter), Extranodal disease; Stage III or Stage IV cHL based on Lugano criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic lymphoma therapy (brentuximab vedotin)
Exception: Patients with prior treatment for indolent lymphoma are still eligible for participation as long as they did not receive anthracycline-based therapy.
Prior systemic lymphoma therapy including prior treatment with brentuximab vedotin. Note: Patients with prior treatment for indolent lymphoma are still eligible for participation as long as they did not receive anthracycline-based therapy.
Lab requirements
Blood counts
ANC >1,000 cells/mm3 (≥750 cells/mm3 if lymphoma involvement of the bone marrow or spleen); Platelets ≥75,000/mm3 (≥50,000/mm3 if lymphoma involvement of the bone marrow or spleen); Hemoglobin >9 g/dL (>8 g/dL in case of bone marrow involvement by lymphoma)
Kidney function
Creatinine within normal institutional limits or creatinine clearance ≥40 mL/min
Liver function
Serum total bilirubin ≤2x ULN (except patients with Gilberts syndrome); AST and ALT ≤2.5x institutional ULN (≤3x institutional ULN if lymphoma involvement of the liver)
Patients must have normal organ and marrow function as defined below: Absolute neutrophil count (ANC) >1,000 cells/mm3 independent of growth factor support within 7 days of study entry (≥750 cells/mm3 if lymphoma involvement of the bone marrow or spleen). Platelets ≥75,000 platelets/mm3 independent of transfusion support within 7 days of study entry (≥50,000 platelets/mm3 independent of transfusion support within 7 days of study entry if lymphoma involvement of the bone marrow or spleen). Hemoglobin >9 g/dL or >8 g/dL in case of bone marrow involvement by lymphoma independent of transfusion support within 7 days of study entry. Serum total bilirubin ≤2x upper limit of normal (ULN; except patients with Gilberts syndrome). Aspartate aminotransferase (AST; serum glutamic-oxaloacetic transaminase) and alanine transaminase (ALT; serum glutamic-pyruvic transaminase) ≤2.5x institutional ULN (≤3x institutional ULN if lymphoma involvement of the liver). Creatinine within normal institutional limits or creatinine clearance ≥40 mL/min (as estimated by the Cockcroft-Gault equation or alternative formula according to institutional guidelines) for patients with creatinine levels above institutional normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify